These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 11750255)

  • 1. 5alpha-reductase inhibitors: what role should they play?
    Kaplan SA
    Urology; 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. PubMed ID: 11750255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finasteride for benign prostatic hyperplasia.
    Tacklind J; Fink HA; Macdonald R; Rutks I; Wilt TJ
    Cochrane Database Syst Rev; 2010 Oct; 2010(10):CD006015. PubMed ID: 20927745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study.
    Albertsen PC; Pellissier JM; Lowe FC; Girman CJ; Roehrborn CG
    Clin Ther; 1999 Jun; 21(6):1006-24. PubMed ID: 10440624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
    Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of different drugs on the treatment of benign prostate hyperplasia].
    Li NC; Wu SL; Jin J; Qiu SP; Kong CZ; Song YS; Ye ZQ; Sun G; Sun YH; Sun YC; Wang XF; Na YQ
    Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(14):947-50. PubMed ID: 17961376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
    Glassman DT; Chon JK; Borkowski A; Jacobs SC; Kyprianou N
    Prostate; 2001 Jan; 46(1):45-51. PubMed ID: 11170131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks IR; MacDonald R
    Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    Wilt TJ; Howe W; MacDonald R
    BJU Int; 2002 Feb; 89(3):214-25. PubMed ID: 11856101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
    N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WITHDRAWN: Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks I; Macdonald R
    Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD003851. PubMed ID: 21901686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
    Marberger MJ
    Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.
    Kirby RS; Roehrborn C; Boyle P; Bartsch G; Jardin A; Cary MM; Sweeney M; Grossman EB;
    Urology; 2003 Jan; 61(1):119-26. PubMed ID: 12559281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
    Kaplan SA; Roehrborn CG; McConnell JD; Meehan AG; Surynawanshi S; Lee JY; Rotonda J; Kusek JW; Nyberg LM;
    J Urol; 2008 Sep; 180(3):1030-2; discussion 1032-3. PubMed ID: 18639298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical therapy for benign prostatic hyperplasia: a review of the literature.
    Clifford GM; Farmer RD
    Eur Urol; 2000 Jul; 38(1):2-19. PubMed ID: 10859436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ; Howe RW
    BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
    Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.